Smoking in the USA: 11 Questions on the Latest Numbers

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

The positive topline data from the phase 3 ACHIEVE-1 trial suggest the small molecule GLP-1 mimetic could compete with blockbuster weekly injectables for reducing weight, A1c.

Linda Stein Gold, MD;Sydney Jennings

March 9th 2025

GSK: 3-Year Efficacy Data for Arexvy in Older Adults Published in Lancet Respiratory Medicine

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

A single dose of the RSVPreF3 demonstrated a cumulative efficacy of 62.9% against RSV-LRTD across 3 seasons in adults aged 60 years and older.

Keith A. Reynolds

October 1st 2024

Emergency Care for Cannabis Use Associated with Increased Risk for Dementia in Adults: Canadian Population Study

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Emergency Care for Cannabis Use May Increase Risk for Dementia in Adults / image credit University of Ottawa

New Insights Into Treatment Resistant Depression Show Gaps in Care: Daily Dose

Adults with a cannabis-related acute care visit or hospitalization were at 23% and 72% greater risk of a new dementia diagnosis within 5 years, a new study finds.

Sydney Jennings

Lilly’s Oral GLP-1 Orforglipron Shows Significant and Competitive A1c and Weight Reductions in Phase 3 Trial

Your daily dose of the clinical news you may have missed.

Related Content

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

The positive topline data from the phase 3 ACHIEVE-1 trial suggest the small molecule GLP-1 mimetic could compete with blockbuster weekly injectables for reducing weight, A1c.

Linda Stein Gold, MD;Sydney Jennings

March 9th 2025

GSK: 3-Year Efficacy Data for Arexvy in Older Adults Published in Lancet Respiratory Medicine

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

A single dose of the RSVPreF3 demonstrated a cumulative efficacy of 62.9% against RSV-LRTD across 3 seasons in adults aged 60 years and older.

Keith A. Reynolds

October 1st 2024

Emergency Care for Cannabis Use Associated with Increased Risk for Dementia in Adults: Canadian Population Study

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

New Insights Into Treatment Resistant Depression Show Gaps in Care: Daily Dose

Adults with a cannabis-related acute care visit or hospitalization were at 23% and 72% greater risk of a new dementia diagnosis within 5 years, a new study finds.

Sydney Jennings